

We are advancing a deep and broad portfolio of product candidates derived from our four drug classes focused on the treatment of cancer, infectious diseases and other serious diseases of unmet patient need:

## Oncology

Drug class	Platform	Product candidate	Indication (target)	Phase 1	Phase 1/2	Phase 2	Phase 3	BioNTech rights <sup>1</sup>	Collaborator/ Partner
mRNA	FixVac	BNT111	Advanced, R/R melanoma					Fully owned <sup>2</sup>	
		BNT113	Metastatic/ R/R HPV16+ head and neck cancer						
		BNT116	1L metastatic NSCLC Advanced/metastatic NSCLC						
	iNeST	BNT122 (autogene cevumeran)	1L advanced melanoma					Collaboration	Genentech <sup>3</sup>
			Adjuvant colorectal cancer						
			Adjuvant pancreatic ductal adenocarcinoma Multiple solid tumors						
	RiboMabs	BNT142	Multiple solid tumors (CD3xCLDN6)					Fully owned	
	RiboCytokines	BNT151	Multiple solid tumors (IL-2 variant)					Fully owned	
		BNT152 + BNT153	Multiple solid tumors (IL-7, IL-2)					Fully owned	
Cell therapies	CAR T cells + CARVac	BNT211	Multiple solid tumors (CLDN6)					Fully owned	
	Neoantigen-based T cells	BNT221	Refractory metastatic melanoma					Fully owned	
Protein-based therapeutics	Next-generation immune checkpoint modulators	BNT311 / GEN1046 (acasanlimab)	aPD(L)1-R/R metastatic NSCLC (PD-L1x4-1BB)					Collaboration	Genmab
			2L endometrial cancer (PD-L1x4-1BB)						
			Multiple solid tumors (PD-L1x4-1BB)						
		BNT312 / GEN1042	Multiple solid tumors (CD40x4-1BB) <sup>4</sup>						
		BNT313 / GEN1053	Multiple solid tumors (CD27)						
		BNT314 / GEN1059	Multiple solid tumors (EpCAMx4-1BB)						
	BNT322 / GEN1056	Multiple solid tumors							
	Targeted cancer antibodies	BNT316 / ONC-392 (gotistobart)	aPD(L)1-R/R metastatic NSCLC (CTLA-4)					Collaboration	OncoC4
			Platinum-resistant ovarian cancer (CTLA-4)						
			Metastatic castration-resistant prostate cancer (CTLA-4) Multiple solid tumors (CTLA-4)						
Antibody-drug conjugates	BNT323 / DB-1303	Multiple solid tumors (HER2)					Collaboration	Duality Bio	
		2L+, HR+/HER2-low metastatic breast cancer (HER2)							
		BNT324 / DB-1311	Multiple solid tumors (B7H3)						
		BNT325 / DB-1305	Multiple solid tumors (TROP2)						
SMI <sup>5</sup>	Toll-like receptor binding	BNT411	Multiple solid tumors (TLR7)					Fully owned	

